# Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19

> **NCT04407182** · PHASE2 · COMPLETED · sponsor: **Catalysis SL** · enrollment: 60 (actual)

## Conditions studied

- Covid-19
- Sars-CoV2
- Diabete Mellitus
- Cardiopathy
- Pulmonary Disease
- Renal Disease
- Liver Diseases

## Interventions

- **DIETARY_SUPPLEMENT:** Viusid and Asbrip

## Key facts

- **NCT ID:** NCT04407182
- **Lead sponsor:** Catalysis SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-04
- **Primary completion:** 2020-08-01
- **Final completion:** 2020-10-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04407182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04407182, "Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04407182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*